This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...

The executive spoke at the 44 th annual 2026 JP Morgan Healthcare Conference in San Francisco early on Monday, January 12.

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

Janux Therapeutics, Inc. (Nasdaq: JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor ...

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

If you are wondering whether Bristol-Myers Squibb is offering good value at around US$54.94 per share, you are not alone. Many investors are asking the same question right now. The stock has had mixed ...

Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...